Press release                                                                                                                                             Ecully, 4 November 2019

Patent issued in Europe for the Mont-Blanc MIS range

Spineway, specialist in surgical implants and instruments for treating disorders of the spinal column (spine), has just been granted a new patent for its innovative Mont-Blanc MIS range in the USA.

Since 2008, Spineway has invested in industrial property, enabling it to display a portfolio of more than 35 patents and confirm its status as an innovative company. In line with its strategy of strengthening its higher value-added product lines, Spineway pursues its sustained intellectual property policy, which results in the regular filing of new patents.

After the United States, the European Patent Office (EPO) has just awarded Spineway a patent for its Mont-Blanc MIS range, granting it a monopoly of exploitation and the protection of its innovation in nearly 40 countries for a period of 20 years. This recognition confirms the innovative nature of its MIS range, marking an important step for its redeployment.

With this patent, which strengthens the Group's portfolio, Spineway will continue its innovation strategy and strengthen its positions in mature countries.


Find out all about Spineway at

This press release has been prepared in both English and French. In case of discrepancies, the French version shall prevail.

Spineway designs, manufactures and markets innovative implants and surgical instruments for treating severe disorders of the spinal column.
Spineway has an international network of over 50 independent distributors and 90% of its revenue comes from exports.
Spineway, which is eligible for investment through FCPIs (French unit trusts specializing in innovation), has received the OSEO Excellence award since 2011 and has won the Deloitte Fast 50 award (2011). Rhône Alpes INPI Patent Innovation award (2013) – INPI Talent award (2015).
ISIN: FR0011398874 - ALSPW              



Shareholder-services line
Available Tuesday through Thursday
(10 a.m. – 12 p.m.)
+33 (0)811 045 555



Finance et Communication

Investor relations
Solène Kennis